Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
2017
Authors:
Stojanović, Ivana D.Dimitrijević, Mirjana
Vives-Pi, Marta
Mansilla, Maria Jose
Pujol-Autonell, Irma
Rodríguez-Fernandez, Silvia
Palova-Jelínkova, Lenka
Funda, David P.
Gruden-Movsesijan, Alisa
Sofronić-Milosavljević, Ljiljana
Hilkens, Catharien M. U.
Caceres, Eva Martinez
Miljković, Đorđe
Document Type:
Article (Published version)
,
© 2017 Bentham Science Publishers
Metadata
Show full item recordAbstract:
Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Keywords:
Cell-based tolerogenic therapy; Multiple sclerosis; Regulatory T cells; Rheumatoid arthritis; Tolerogenic dendritic cells; Type 1 diabetesSource:
Current Pharmaceutical Design, 2017, 23, 18, 2623-2643
DOI: 10.2174/1381612823666170214120708
ISSN: 1381-6128
PubMed: 28201972